Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Hereditary Cancer in Clinical Practice
Published in: Hereditary Cancer in Clinical Practice 1/2017

Open Access 01-12-2017 | Review

The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation

Authors: Agnieszka Strumidło, Sylwia Skiba, Rodney J. Scott, Jan Lubiński

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2017

Login to get access

Abstract

Germline variants within BRCA1 or BRCA2 genes account for approximately 25% of familial aggregations of breast-ovarian cancers. Low or no expression of BRCA1 in breast and ovarian cancers is associated with a good clinical response to treatment with platinum therapies and PARP1 inhibitors. Recent studies demonstrated that microRNAs - small non-coding RNAs, involved in the control of gene expression, can decrease BRCA1 expression by targeting the 3’UTR region of the gene. This article reviews reported relationships between various miRNAs, such as miRNA-9, miRNA-146a, miRNA-182 miRNA-218, miRNA-638 and the response to cytostatic drugs, mainly to platins and PARP1 inhbitors, for the treatment of breast and ovarian cancer associated with BRCA1 mutations.
Literature
1.
2.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M. Parkin D M, Forman D, bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer. 2015;136:E359–86.
3.
Kluzek K, Białkowska A, Koczorowska A. Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy. Postepy Hig Med Dosw. 2012;66:372–84.CrossRef
4.
Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer. 2016;115:1157–73.CrossRefPubMedPubMedCentral
5.
Vos S, Vesuna F, Raman V, van Diest PJ, van der Groep P. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers. Oncotarget. 6:31.
6.
Behrendt K, Suwiński R, Grzybowska E, Zientek H, Rogozińska-Szczepka J, Utracka-Hutka B, Nowicka E, Lange D. Clinical course of breast cancer in carriers of BRCA1 germline mutations. Współczesna Onkologia. 2003;7(10):742–53.
7.
8.
Berhuck A, Heron K, Carney ME, Lancaster JM, Fraser EG, Vinson VL, Deffenbaugh AM, Miron A, Marks JR, Futreal PA, Frank TS. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Caner Res. 1998;4:2433–7.
9.
Knudson A. Retinoblastoma: a prototypic hereditary neoplasm. Semin Oncol. 1978;5:57–60.PubMed
10.
Mueller C. Calvin D Roskelley, regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res. 2003;5(1):45–52.CrossRefPubMed
11.
Matamala N, Vargas MT, González-Cámpora R, Arias JI, Menéndez P, Andrés-León E, Yanowsky K, Llaneza-Folgueras A, Miñambres R, Martínez-Delgado B, Benítez J, MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression. Oncotarget. 7(15):20068–79.
12.
Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nature Rev Mol Cell Biol. 2009;10(2):126–39.CrossRef
13.
Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006;66:7390–4.CrossRefPubMed
14.
Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson Band Reich R. miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med. 2011;15(7):1593–602.CrossRefPubMedPubMedCentral
15.
16.
17.
Tchounwou PB, Dasari S. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;0:364–78.
18.
Byrski T, Dent R, Blecharz P, Foszczynska-Kloda M, Gronwald J, Huzarski T, et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res. 2012;14(4):R110. https://​doi.​org/​10.​1186/​bcr3231.
19.
Nowsheen S, Yang ES. The intersection between DNA damage response and cell death pathways. Exp Oncol. 2012;34(3):243–54.PubMedPubMedCentral
20.
Budzyński M, Grenda A. Filip A. MicroRNA molecule as an important component of the mechanisms regulating the expression of genes associated with cancer. 2014;64(1):48–60.
21.
22.
Sun C, Li N, Yang Z, Zhou B, He Y, Weng D, Fang Y, Wu P, Chen P, Yang X, Ma D, Zhou J, Chen G. miR-9 Regulation of BRCA1 and Ovarian Cancer Sensitivity to Cisplatin and PARP Inhibition. JNCI. 2013;105(22).
23.
Gu Y, Zhang M, Peng F, Fang L, Zhang Y, Liang H, Zhou W, Ao L, Guo Z. The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2. Oncotarget. 6(4):2397–406.
24.
Suhwan Ch, Sharan SK. BRCA1 and MicroRNA's: Emerging Networks nad potential therapeutic targets. Mol Cells. 2012;34:425–32.CrossRef
25.
Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K, Weinstock DM, Gorospe M, Harris AL, Helleday T, Chowdhury D. miR-182-mediated down-regulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 2011;41(2):210–20.CrossRefPubMed
26.
Kahlert C, Klupp F, Brand K, Lasitschka F, Diederichs S, Kirchberg J, Rahbari N, Dutta S, Bork U, Fritzmann J, Reissfelder C, Koch M, Weitz J. Invasion front-specific expression and prognostic significance of microRNA in colorectal liver metastases. Cancer Sci. 2011;102:1799–807.CrossRefPubMed
27.
He X, Xiao X, Dong L, Wan N, Zhou Z, Deng H, Zhang X. MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1. Tumor Biol. 2015;36:2065–75.CrossRef
28.
Zavala V, Pérez-Moreno E, Tapia T, Camus M, Carvallo P. miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival. Cancer Biomarkers. 2016;16:99–107.CrossRefPubMed
29.
Zhang X, Wei J, Zhou L, Zhou C, Shi J, Yuan Q, Yang M, Lin D. A functional BRCA1 coding sequence genetic variant contributes to risk of esophageal squamous cell carcinoma. Carcinogenesis. 2013;34:2309–13.CrossRefPubMed
30.
Tan X, Peng J, Fu Y, An S, Rezaei K, Tabbara S, Teal CB, Man Y, Brem RF, Fu SW. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer, Tan et al. Breast Cancer Res. 2014;16:435.
Metadata
Title
The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation
Authors
Agnieszka Strumidło
Sylwia Skiba
Rodney J. Scott
Jan Lubiński
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 1/2017
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/s13053-017-0076-7

Other articles of this Issue 1/2017

Hereditary Cancer in Clinical Practice 1/2017 Go to the issue

Case report

Late onset asymptomatic pancreatic neuroendocrine tumor – A case report on the phenotypic expansion for MEN1

Research

Anxiety and depression symptoms among women attending group-based patient education courses for hereditary breast and ovarian cancer

Research

Emotional impact on the results of BRCA1 and BRCA2 genetic test: an observational retrospective study

Review

Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review

Case report

A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma

Research

Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits